- LION´s SRS to provide integration and access technology to link bioinformatics data with patient information
Cambridge, MA, USA, Heidelberg, Germany, March 10, 2004 – LION bioscience AG (Nasdaq: LEON) and DigiGenomics Co., Ltd. announced today a joint project with Wan Fang Municipal Hospital of Taipei for the development of a SARS (Severe Acute Respiratory Syndrome) Knowledge Management System in Taiwan. LION´s SRS technology, including the SRS Relational module, will be used to access and integrate data from bioinformatic and medical databases with a unique architecture that will give physicians rapid access to medical records, clinical assays and recommended treatments. The new system aims to help control the spread of SARS by reducing misdiagnosis and infection control failures. Financial details of the project were not disclosed.
Users of the system will benefit from a single graphical user interface, with access to every applicable database. This will help prevent medical error in taking care of SARS patients. The system will be promoted to Taiwanese health industry and government health officials, and is scheduled for launch in the fourth quarter 2004. A software demonstration for the SARS KM system is planned at Wan Fang Hospital, one of the major hospitals in Taipei where SARS had a serious impact.
“We are very pleased that LION is involved in this project and that our technology will play a central role in the development of this unique SARS Knowledge Management System,” said Dr. Jason Theodosiou, LION bioscience Vice President Sales Europe & Asia Pacific.”
SRS is a proven, scalable and robust data integration platform that provides fast access to diverse life science data - genetic, protein, cellular, molecular and clinical - from public and proprietary sources, regardless of data format. SRS is used in more than 300 commercial and academic sites delivering genomic data daily to thousands of users around the globe. SRS is the clear market leader for bioinformatics data integration, providing global bioinformatics platforms for pharmaceutical companies such as Eli Lilly, Johnson&Johnson and AstraZeneca, as well as forming the basis of genomics portals for leading data providers such as Celera, Incyte, Derwent and Affymetrix.
About DigiGenomics Co., Ltd.
Founded in 2000, DigiGenomics is a pioneering informatics-driven biotech service company, focusing on bio-knowledge management and informatics-driven drug discovery services. Integrating computer science, genomic, and proteomic technologies, DigiGenomics provides scientists with the opportunities to advance and accelerate their research, spanning from target identification and validation to drug discovery and development. DigiGenomic´s mission is accompanied by uncompromising integrity, innovative science and technology, and high-quality implementation. For more information please go to www.digigenomics.com.
For further information please contact:
+49 (0) 6221-4038 158
About LION bioscience
LION bioscience (ISIN: DE0005043509, Reuters: LIOG, Bloomberg: LIO, Nasdaq: LEON) provides proven information and knowledge management solutions to significantly improve life science R&D performance and productivity. Since it was founded in 1997, the company has become a recognized leader in the area of life sciences informatics. LION has operations worldwide with its headquarter in Heidelberg, Germany, and offices in Cambridge, UK, Cambridge, MA, and San Diego, CA, USA. LION’s products are distributed by CTC Systems in Japan and DigiGenomics in Taiwan and Korea.
LION’s (https://www.netgenics.com) solutions are used by more than 27,000 researchers at 300 academic and industrial customers globally. LION’s offerings include SRS for bioinformatics data access, LION Target Engine™ for target identification and validation, LION Lead Engine™ for lead identification and optimization, iDEA pkEXPRESSä with analysis and prediction tools for ADME, and LION SolutionCenter™ professional services.
Except for the historical information contained herein, the matters set forth in this press release are forward looking within the meaning of the Private Securities Litigation Reform Act of 1995, and other applicable U.S. and German laws. These forward-looking statements may include projections, estimates, targets, goals and descriptions of future events. Such statements are based on the current targets that LION has set itself and on LION’s current expectations, each of which is subject to risks and uncertainties. LION’s actual results may vary materially from those targeted, expected or projected because of factors such as uncertainties relating to technologies, product and solution development, acceptance by the market of LION’s offerings, market or industry trends, success of LION’s business model and strategy, competition, exchange rate fluctuations, cost or pricing of LION’s products and solutions, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, or patent or copyright protection and litigation. We refer you to LION’s Annual Reports on Form 20-F, as filed with the Securities and Exchange Commission (SEC), as well as LION’s SEC filing, as filed on September 30, 2003, in which these and other risk factors are discussed. LION expressly disclaims any obligation or undertaking to release publicly any updates, revisions or corrections to any forward-looking statements or historical information contained in this announcement, whether as a result of new information, change of assumptions or business model, future developments or otherwise. LION bioscience®, Life Science Informatics™, LION DiscoveryCenter™, LION SolutionCenter™, LION Hosted Services™, LION Target Engine™, LION Lead Engine™, LSI™, bioSCOUT®, arraySCOUT™, arrayTAG™, arrayBASE™, genomeSCOUT™, pathSCOUT™, πSCOUT™ and iDEA™ are either registered trademarks of LION bioscience AG or its subsidiaries in the United States and/or other countries, or there are pending applications by LION bioscience AG or its subsidiaries for these trademarks in the United States and/or other countries. The names of actual companies and products mentioned herein may be the trademark of the respective owners.
| || |